Low-calcium lactate peritoneal dialysis fluid medicine composition containing azulene sulfonate and salt thereof

Abstract

The invention discloses a low-calcium lactate peritoneal dialysis fluid medicine composition. The low-calcium lactate peritoneal dialysis fluid medicine composition contains glucose, sodium chloride, calcium chloride, magnesium chloride, alkali, azulene sulfonate and salt or ester in terms of azulene sulfonate and water. The adverse effects of a peritoneal dialysis fluid on peritonea can be reduced.

Description

technical field [0001] The invention relates to a low-calcium lactate peritoneal dialysate pharmaceutical composition containing azulene sulfonic acid and its salts. Background technique [0002] Peritoneal dialysis (PD) is an important renal replacement therapy (CRRT) for patients with end-stage renal failure. Compared with hemodialysis, it has the advantages of wide application range, high dialysis efficiency, good preservation of residual renal function, and high quality of life for patients. , occupies an increasingly important position in the alternative therapy of chronic renal failure. The key to successful peritoneal dialysis is a well-functioning ultrafiltration peritoneum and peritoneal dialysate. Due to the long-term nature of peritoneal dialysis treatment, the ultrafiltration performance of the peritoneum is often affected by various factors and changes during the treatment process, and this change is irreversible, which will eventually cause the loss of the per...

AI Technical Summary

Problems solved by technology

The traditional peritoneal dialysis solution is lactate dialysate with different concentrations of glucose as the osmotic agent. Years of clinical practice have shown that although PD has played a very important role in the treatment of chronic renal failure, from the perspective of human physiology At present, the dialysate commonly used still has the following problems: (1) the dialysate uses glucose as the main osmotic agent, because it can be absorbed by the peritoneum, so its osmotic effect lasts for a short time, and it is difficult to achieve ideal liquid and solute removal; (2) Certain components in the dialysate (glucose and bases, etc.) can activate inflammatory cytokines (growth factors, nitric oxide synthase), long-term use can cause chronic inflammatory changes in the peritoneum, and promote peritoneal fibrosis and thickening (3) After the glucose in the dialysate is decomposed in the body, a large amount of glycated end products (AGEs) can be produced, and the latter can be widely deposited in the body, especially after deposition in the blood vessel wall and peritoneal interstitium, it can cause interstitial (4) Glucose can be degraded in high-temperature disinfection to form a series of glucose degradation products (GDPs), which can directly damage peritoneal cells and promote the formation of AGE; (5) Buffer alkali in dialysate Most of them use lactate, which must first be metabolized by the liver and converted into bicarbonate before they can correct acidosis, so it often has certain limitations for some patients with liver disease

[0003] There are also literatures that high concentrations of glucose and glucose degradation products (GDPs) have a direct toxic effect on the cells of peritoneal tissue by destroying the tight junctions, gap junctions and adhesive junctions of peritoneal mesothelial cells, as well as oxidative stress and mitochondrial pathways. Apoptosis of peritoneal mesothelial cells, resulting in loss of peritoneal mesothelial cells, ultimately destroying the structural integrity of the peritoneum

[0004] In short, the mechanism of the occurrence and development of peritoneal fibrosis associated with peritoneal dialysis is very complex.

Images